The research team led by XIA Hongguang from the Zhejiang University School of Medicine/ Liangzhu Laboratory published their latest findings in an open-access article entitled “ARIh7 Signaling Promotes Anti-tumor Immunity by Targeting PD-L1 for Proteasomal Degradation” in the journal Nature Communications on April 20. In this study, researchers screened out several compounds as inducers of PD-L1 degradation, identified ARIh7 as the E3 ubiquitin ligase responsible for targeting PD-L1 to degradation and delineated the mechanism of PD-L1 degradation and cancer escape from immunity via EGFR-GSK3α-ARIh7 signaling. This study suggests that ARIh7 might become a potential drug target to boost immunotherapy.